Is Medicamen Biotech a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Biotech Ltd is a below average quality company .

Is Medicamen Biotech undervalued or overvalued?

The key valuation ratios of Medicamen Biotech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Medicamen Biotech share price return in the past 10 years?

Medicamen Biotech Ltd share price has appreciated 43.3% annually (CAGR) over the past ten years.

Is Medicamen Biotech a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Medicamen Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Medicamen Biotech Ltd - Stock Valuation and Financial Performance

Name: Medicamen Biotech
Brand: Medicamen Biotech

BSE: 531146 | NSE: MEDICAMEQ | Pharmaceuticals & Drugs | Small Cap

Place order

Medicamen Biotech Share Price

₹537.65 -8.65 -1.58%
as on 31-Oct'24 16:01

10 Year X-Ray of Medicamen Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.6%	11.4%	24.1%	24.9%	20.2%	15.3%	13.1%	12.8%	11%	10.1%	-
Value Creation Index ⓘ	-0.2	-0.2	0.7	0.8	0.4	0.1	-0.1	-0.1	-0.2	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	77.8	67.3	82.5	112	123	117	110	115	138	172	173
Sales YoY Gr.	-	-13.5%	22.6%	35.2%	10%	-4.3%	-6.1%	4.8%	19.4%	25%	-
Adj EPS ⓘ	-0	0.1	4.8	7.7	8.8	9.2	10	11.4	11	9.7	8.8
YoY Gr.	-	NA	4650%	62.5%	14.1%	4.8%	7.8%	14.3%	-2.9%	-12.5%	-
BVPS (₹) ⓘ	17.8	17.9	24.7	63.7	73.7	98.6	104.5	114.8	146.8	159.3	161.1
Adj Net Profit ⓘ	0	0.1	5	9	10.3	11.3	12.2	13.9	14	12.3	11
Cash Flow from Ops. ⓘ	-3.3	6.2	3.6	-5.5	4.3	11.7	13	4.8	-3.5	-0.3	-
Debt/CF from Ops. ⓘ	-6.3	3.3	4.9	-2.7	2.7	1	1.5	5.4	-7.4	-121.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.2%	7.1%	16.1%	25%
Adj EPS ⓘ	NA	1.9%	-1%	-12.5%
BVPSⓘ	27.6%	16.7%	15.1%	8.6%
Share Price	43.3%	9.1%	-1.5%	-18.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-0.2	0.6	22.4	17.8	12.8	10.8	9.5	9.8	8.2	6.1	5.5
Op. Profit Mgn % ⓘ	6.5	8.2	14.1	15.1	14.3	15.5	18.2	20.9	17.9	15.8	13.5
Net Profit Mgn % ⓘ	-0.1	0.2	6.1	8.1	8.4	9.6	11	12	10.1	7.1	6.4
Debt to Equity ⓘ	1.2	1.1	0.7	0.2	0.1	0.1	0.2	0.2	0.1	0.2	-
Working Cap Days ⓘ	201	230	197	196	235	287	310	332	358	342	165
Cash Conv. Cycle ⓘ	42	42	37	64	74	71	66	88	128	118	76

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.10%

Sales growth is good in last 4 quarters at 20.10%

Return on Equity has declined versus last 3 years average to 5.50%

Net Profit has been subdued in last 3 years -0.98%

Latest Financials - Medicamen Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8.8	6.1
TTM Sales (₹ Cr.)	173	180
BVPS (₹.) ⓘ	161.1	158.2
Reserves (₹ Cr.) ⓘ	199	195
P/BV ⓘ	3.33	3.39
PE ⓘ	61.22	88.09

From the Market
52 Week Low / High (₹)	356.75 / 685.55
All Time Low / High (₹)	2.25 / 1219.00
Market Cap (₹ Cr.)	682
Equity (₹ Cr.)	12.7
Face Value (₹)	10
Industry PE ⓘ	46.8

Management X-Ray of Medicamen Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Medicamen Biotech

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Medicamen Biotech

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	78	67	82	112	123	117	110	115	138	172
Operating Expenses ⓘ	73	62	71	95	105	99	90	91	113	145
Manufacturing Costs	21	20	19	30	22	25	29	24	33	36
Material Costs	37	29	37	49	69	60	47	44	53	72
Employee Cost	5	5	7	9	8	9	9	15	19	22
Other Costs ⓘ	9	8	8	7	6	5	5	9	9	15
Operating Profit ⓘ	5	6	12	17	17	18	20	24	25	27
Operating Profit Margin (%)	6.5%	8.2%	14.0%	15.1%	14.2%	15.4%	18.2%	20.9%	17.9%	15.8%
Other Income ⓘ	1	1	0	2	4	2	1	2	2	2
Interest ⓘ	4	4	4	3	1	1	2	2	3	6
Depreciation ⓘ	2	2	2	2	2	2	3	6	6	7
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	1	6	14	18	17	17	18	17	17
Tax ⓘ	0	0	1	4	5	4	4	3	2	4
Profit After Tax	0	0	5	10	12	12	12	15	15	13
PAT Margin (%)	0.6%	0.7%	6.3%	9.1%	9.8%	10.4%	11.3%	12.9%	10.9%	7.7%
Adjusted EPS (₹)	0.5	0.5	4.9	8.6	10.3	10.0	10.2	12.2	11.9	10.5
Dividend Payout Ratio (%)	0%	0%	0%	12%	10%	5%	10%	8%	8%	10%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	17	18	26	75	87	122	134	148	193	209
Share Capital ⓘ	10	10	11	12	12	12	12	12	13	13
Reserves ⓘ	7	8	15	63	75	110	122	136	180	196
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	20	18	17	14	12	10	17	24	24	30
Long Term Debt	5	4	2	0	0	2	6	5	1	1
Short Term Debt	16	15	14	14	12	8	11	19	23	29
Trade Payables	27	19	22	22	31	32	30	42	46	38
Others Liabilities ⓘ	5	5	9	7	8	12	11	11	13	15
Total Liabilities ⓘ	69	60	73	118	137	176	192	225	275	292
Fixed Assets
Gross Block	35	36	38	46	47	58	116	124	130	136
Accumulated Depreciation	15	17	19	20	22	24	26	32	38	45
Net Fixed Assetsⓘ	20	19	19	25	24	34	90	92	92	91
CWIP ⓘ	0	0	0	0	15	40	0	0	0	0
Investmentsⓘ	0	0	0	0	0	2	2	2	4	8
Inventories	13	11	14	14	15	17	5	27	45	59
Trade Receivables	27	16	26	38	43	44	50	61	60	48
Cash Equivalents	2	3	3	23	9	2	3	4	20	15
Others Assetsⓘ	7	11	11	17	30	37	43	39	53	71
Total Assets ⓘ	69	60	73	118	137	176	192	225	275	292

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-3	6	4	-5	4	12	13	5	-3	0
PBT ⓘ	0	0	6	14	17	17	17	18	17	17
Adjustment ⓘ	4	5	5	4	2	3	3	7	9	11
Changes in Working Capital ⓘ	-8	1	-8	-23	-11	-3	-3	-17	-33	-25
Tax Paid ⓘ	0	0	0	-1	-4	-4	-4	-3	3	-3
Cash Flow From Investing Activity ⓘ	0	-1	-2	-8	-15	-39	-18	-8	-8	-9
Capex	0	-1	-2	-8	-16	-38	-18	-9	-6	-6
Net Investments	0	0	0	0	0	-2	0	0	-2	-4
Others ⓘ	0	0	0	0	1	0	0	0	1	1
Cash Flow From Financing Activityⓘ	3	-5	-1	33	-4	21	6	4	28	3
Net Proceeds from Shares ⓘ	1	1	3	39	0	25	0	0	31	3
Net Proceeds from Borrowing ⓘ	4	-1	-1	-2	0	2	4	-1	-4	0
Interest Paid ⓘ	-3	-3	-3	-2	-1	-1	-1	-1	-3	-4
Dividend Paid ⓘ	0	0	0	-1	0	-1	-1	-1	-1	-1
Others ⓘ	0	-1	0	0	-3	-4	3	8	5	5
Net Cash Flow ⓘ	0	0	0	20	-14	-6	1	1	17	-6

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	2.66	2.76	23.5	20.12	14.96	11.86	10.06	11.12	9.2	6.85
ROCE (%)	11.58	11.36	24.1	24.91	20.22	15.26	13.12	12.82	10.95	10.13
Asset Turnover Ratio	1.17	1.05	1.24	1.17	0.96	0.75	0.6	0.55	0.55	0.61
PAT to CFO Conversion(x)	N/A	N/A	0.8	-0.5	0.33	1	1.08	0.33	-0.2	0
Working Capital Days
Receivable Days	110	115	92	105	122	136	155	175	161	115
Inventory Days	62	67	55	46	44	50	37	51	95	111
Payable Days	250	284	200	164	138	191	237	299	302	212

Medicamen Biotech Ltd Stock News

Medicamen Biotech Ltd FAQs

What is the share price of Medicamen Biotech?

Company share prices are keep on changing according to the market conditions. The closing price of Medicamen Biotech on 31-Oct-2024 16:01 is ₹537.6.

What is the market cap of Medicamen Biotech?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Medicamen Biotech stood at ₹681.8.

What is the P/E ratio of Medicamen Biotech?

The latest P/E ratio of Medicamen Biotech as of 31-Oct-2024 16:01 is 61.22.

What is the P/B ratio of Medicamen Biotech?

The latest P/B ratio of Medicamen Biotech as of 31-Oct-2024 16:01 is 3.33.

What is the 52-week high and low of Medicamen Biotech?

The 52-week high of Medicamen Biotech is ₹685.5 and the 52-week low is ₹356.8.

What is the TTM revenue of Medicamen Biotech?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Medicamen Biotech is ₹173.4 ( Cr.) .

About Medicamen Biotech Ltd

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.

In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.

In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.

Product range of the company includes:

The company is the Manufacturer and supplier of Comprehensive range of products: